This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
From AI models that boost sales to robots that slash production costs, advanced technologies are transforming both top-line growth and bottom-line efficiency. Business leaders dont need to be technology experts to grasp this shift; they need vision and urgency. in returns for every $1 invested , with some seeing over $10 in ROI.
startups raised half a billion dollars apiece, and another eight raised $100 million or more, with industries from cybersecurity to biotech to AI represented. The latest startup in the space to get a big chunk of cash is Beta Technologies, maker of electric vertical take-off and landing planes. billion valuation in the process.
Commerce Department said Wednesday it is imposing new export controls on biotechnology equipment and related technology because of national security concerns tied to artificialintelligence and data science. technology to strengthen military capabilities and help design new weapons through AI.
Lambda , $480M, artificialintelligence: Lambda, which offers cloud computing services and hardware for training artificialintelligence software, raised a $480 million Series D co-led by Andra Capital and SGW. Founded in 2013, NinjaOne has raised nearly $762 million, per Crunchbase. billion valuation. billion valuation.
The surge was driven by large funds leading supergiant rounds in capital-intensive businesses in areas such as artificialintelligence, data centers and energy. And not far off from a billion, Pacific Fusion , a nuclear fusion technology company, raised more than $900 million in a round led by General Catalyst.
billion globally went to companies applying advances in artificialintelligence to health-related areas such as medical services and pharmaceutical development, per Crunchbase data. The smash hit of the past year was Tempus AI , an artificialintelligence precision medicine company that went public in June.
OpenAI , $6.6B, artificialintelligence: OpenAI announced its long-awaited raise of $6.6 tied) Poolside , $500M, artificialintelligence: Poolside closed a $500 million Series B led by Bain Capital Ventures. The startup builds artificialintelligence software for programmers. billion, per Crunchbase.
Biotech offerings, while more plentiful, are also running well below prior highs. Below, we pick out winners and losers for venture-backed tech and biotech companies, focusing on large- and medium-sized IPOs. The provider of AI and cloud connectivity technology was recently valued around $18 billion. Just a handful of U.S.
With the constant advancements in technology and research, businesses in this sector require leaders who possess a deep understanding of the scientific landscape and the business acumen to drive growth and innovation. The life sciences industry is known for its unique challenges in recruiting and hiring.
Venture money wasnt concentrated in just one sector, as VCs invested in everything from artificialintelligence to biotech to energy. The Norwalk, Connecticut-based firm did not disclose investor names, instead saying it came from a private investor whose portfolio focuses on global technology and real estate investments.
Atarraya , creator of Shrimpbox, a sustainable “plug-and-play” shrimp farming technology, is swimming to the surface after being in stealth mode since 2019. That grew into aquaculture farming technology with Russek and his team creating a startup company around it called Maricultura Vigas. million in Series A dollars, and a new U.S.
artificialintelligence. ” Marketing AI AI has had a profound effect on many sectors like biotech and cybersecurity, as many startups have added the technology to their platforms. Founded in 2018, the company has raised $172 million, per Crunchbase. It’s a reimagining of the job of being a marketer.”
Close to a third of all global venture funding went to companies in AI-related fields, making artificialintelligence the leading sector for funding. Large early-stage rounds went to data centers, renewable energy, AI, robotics and biotech. billion in 2023 Crunchbase data shows. Seed settled Seed funding trailed in Q4, for now.
xAI , $5B, artificialintelligence: Generative AI startup xAI raised $5 billion in a funding round valuing it at $50 billion, The Wall Street Journal reported. Anthropic , $4B, artificialintelligence: Amazon has agreed to invest another $4 billion in AI startup Anthropic — a ChatGPT rival with its AI assistant Claude.
Biotech/healthcare and cybersecurity dominated the run of big rounds this week, with a few AI startups also seeing good-sized checks. Marea Therapeutics , $190M, biotech: This big biotech round is actually the combination of two rounds. The top five raises this week came from sectors that have seen good heat recently.
The week was especially good for biotech, which led the way with two big raises. Tome Biosciences , $213M, biotech: A big biotech raise hit high on the list this week. Bicara Therapeutics , $165M, biotech: If Bicara Therapeutics looks familiar, it’s because this isn’t its first time on this list.
Best practices for leveraging artificialintelligence and machine learning in 2023 Zero-based budgeting: A proven framework for extending runway Image Credits: Getty Images It’s critical to make every dollar count in this environment, but pulling back too much in the wrong places can reduce momentum across your entire organization. “The
Sifting through the trillions of molecules out there that might have powerful medicinal effects is a daunting task, but the solution biotech has found is to work smarter, not harder. Machine learning has, of course, accelerated work in many fields, biochemistry among them, but he felt that the potential of the technology had not been tapped.
To a great degree, the largest rounds of the year went to a handful of AI companies working on large language models and underlying technologies to scale them. While the Boston startup scene is famous for biotech and deeptech talent, the city has lagged other hubs in creation of ultra-high-valuation AI unicorns.
Just three years after its founding, biotech startup Immunai has raised $60 million in Series A funding, bringing its total raised to over $80 million. Both on the computational side and on the on the lab side, this is really bleeding edge technologies that I think we will be the first to really put together at any kind of real scale.”
When I started at Novanta about five years ago, my first mission was to bring scalability to our Enterprise solutions, as well as developing a digital roadmap to modernize the technology footprint, reduce technical debt, and explore strategies to ensure that we’re growing at scale. We need more women in technology.
Pika , $80M, artificialintelligence: It never takes us long to get to an AI startup on this list. Pika, an artificialintelligence startup that generates video, raised an $80 million round led by Spark Capital that values the Palo Alto, California-based company at $470 million, per Bloomberg. million, per the company.
Biotech and AI had another strong week, as the sectors saw two big nine-figure rounds each — including one for $370 million in biotech. Candid Therapeutics , $370M, biotech: Every week there’s a big biotech raise — and this week there’s one that’s really big. Check out last week’s biggest funding rounds here.
The most valuable new 2024 unicorn company from China is Huawei Technologies smart car subsidiary Yinwang Smart Technology , valued at $16 billion. Healthcare and biotech was the third-highest sector for new unicorns with nine companies. billion, and foundation model companies Moonshot AI , valued at $3.3
Nerdio , $500M, information technology: IT professionals are stretched pretty thin these days, so it makes sense that a company that helps automate some of their work could raise big. Latigo Biotherapeutics , $150M, biotech: Many patients shy away from taking opioids while many doctors are reluctant to prescribe the painkillers.
Safe Superintelligence , $1B, artificialintelligence: AI research lab Safe Superintelligence raised $1 billion from a litany of big-name investors including Andreessen Horowitz and Sequoia Capital. Arsenal Biosciences , $325M, biotech: The big biotech raise of the week went to South San Francisco-based Arsenal Biosciences.
AI, biotech, space tech and cybersecurity also saw good-sized raises. AlphaSense , $650M, artificialintelligence: AI-driven market intelligence platform AlphaSense raised $650 million in funding co-led by Viking Global Investors and BDT & MSD Partners at a $4 billion valuation — a 75% increase from just nine months ago.
OpenAI , $6.6B, artificialintelligence: OpenAI announced its long-awaited raise of $6.6 Poolside , $500M, artificialintelligence: Most weeks a half-billion-dollar round would top this list — but this isn’t most weeks. The startup builds artificialintelligence software for programmers.
After a quiet holiday week, investors were back in action dishing out big rounds to startups in robotics, biotech, healthcare and more. Element Biosciences , $277M, biotech: It’s hard to get through a week without a big biotech raise, and this one’s no different. based companies? Check out The Crunchbase Megadeals Board.
In 2002, prior to founding SymphonyAI, Wadhwani founded Symphony Technology Group , a private equity firm investing in software and technology-enabled services companies. Gen Teare Health and biotech Hinge Health : This is another IPO prediction where were not exactly going out on a limb (pun intended in this case).
Lifebit says it has a patented technology for federating the data around genomic data, allowing researchers to get more insights while keeping the data secure. In an increasingly hot biotech market, protecting IP is key. Existing investors Eurazeo, Pentech Ventures and Beacon Capital also participated.
Understanding the Unique Challenges of Biotech Leadership Recruitment Organizations face some unique challenges when it comes to leadership recruitment in the biotech space. Navigating these unique challenges in biotech leadership recruitment requires a comprehensive understanding of the industry, its trends, and specific needs.
Not exactly sure what was in the water this week, but AI and biotech led the way as happens often. Lambda , $320M, artificialintelligence: In a big week, this was the biggest round. The company offers cloud computing services and hardware for training artificialintelligence software. billion valuation.
His firm has an impact fund focused on the future of food and began investing in alternative proteins in 2016 before expanding that to delivery systems in agriculture technology, he said. While the solution would be to not do that, not doing that would mean produce doesn’t grow as well, he added.
This week’s theme was definitely AI, as many of the largest rounds went to startups using AI in coding or biotech. Xaira Therapeutics , $1B, biotech: The biggest round this week was really big. Augment , $227M, artificialintelligence: AI coding startups made a big splash this week. billion in March 2023.
Halda Therapeutics , $126M, biotech: The big biotech round of the week came from New Haven, Connecticut-based Halda Therapeutics, a biotech startup developing therapies for prostate cancer and breast cancer, which raised a $126 million Series B extension from investors including Deep Track Capital and RA Capital Management.
Sunny Kumar, MD, MBA is a partner at GSR Ventures, an early-stage venture capital firm focused on healthcare technology with more than $3.5 Sunny Kumar. Contributor. Share on Twitter. billion under management. Blood pressure, body temperature, hemoglobin A1c levels and other biomarkers have been used for decades to track disease.
Cosm , $250M, entertainment: Entertainment and technology are intersecting more than ever — and Cosm is just the latest example. Altana AI , $200M, supply chain management: Altana AI, a supply chain management startup, locked up a $200 million Series C investment led by the US Innovative Technology Fund that values the company at $1 billion.
North American startup funding perked up in the second quarter, bolstered by early-stage investment around artificialintelligence. Artificialintelligence remains the runaway favorite investment theme, as AI-focused startups pulled in $16.8 Overall, investors put $45.3 and Canadian startups in the second quarter of 2024.
Eight startups raised $100 million or more this week as a biotech and financial services company led the way. Tekion , $200M, automotive: Providing a software platform to the retail automotive industry may not be the sexiest of technology plays, but it obviously can make a valuable company. Notice anything missing?
The quintet that did raise big were from three of the usual sectors — biotech, energy and AI — however one was from a sector we don’t normally see — a vertical farming agtech startup. FogPharma , $145M, biotech: It sure feels like this will be a big year for biotech startups, as a few make this list every week.
The past quarter was a quirky one for North America startup funding, with a slowdown in some pockets counterbalanced by continued high enthusiasm around artificialintelligence, Crunchbase data shows. While the IPO market wasn’t especially active, we did see a handful of public offerings, predominantly in the biotech sector.
Staying power : 5 strategies for biotech startups to outlast a market downturn , as advised by James Coates. Via, out to bolster its traffic technology offerings, is making good on its promise to do more acquisitions and has now acquired trip planning app Citymapper. Alex found some bullish news for software companies. Big Tech Inc.
We organize all of the trending information in your field so you don't have to. Join 49,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content